Coagulation Cascade and Fibrinogen Biology
The coagulation system (haemostasis: primary (platelet plug) + secondary (coagulation cascade → fibrin clot) + tertiary (fibrinolysis)) involves: (1) Extrinsic pathway: TF (tissue factor; endothelial/monocyte; exposed by vascular injury or inflammation) → TF-VIIa complex → factor X activation → prothrombinase (Xa-Va) → thrombin (IIa) formation; (2) Intrinsic pathway: contact activation (FXII → FXI → FIX → FVIIIa-IXa tenase complex → FXa); (3) Common pathway: thrombin cleaves fibrinogen (Aα, Bβ, γ chains; acute phase protein; hepatic synthesis; baseline 2–4 g/L; rises with inflammation via IL-6→STAT3→FGA/FGB/FGG gene transcription) → fibrin monomers → polymerisation (D:E interactions) → FXIII cross-links (γ-glutamyl-ε-lysine isopeptide bonds) → stable clot. Fibrinolysis: tPA (tissue plasminogen activator; endothelial; converts plasminogen → plasmin; fibrin cofactor; “built-in” clot dissolution) regulated by PAI-1 (plasminogen activator inhibitor-1; the primary tPA inhibitor; acute phase protein; elevated in metabolic syndrome, T2D, obesity, inflammation via NF-κB and TGF-β; high PAI-1 → impaired fibrinolysis → thrombotic tendency).
Spirulina Mechanisms in Coagulation
Fibrinogen Synthesis Suppression via IL-6/STAT3
Fibrinogen (acute phase protein; hepatic synthesis driven by IL-6 → JAK2/STAT3 → FGA/FGB/FGG promoters; also C/EBPβ (NF-IL6) binding; rises 2–5× in acute inflammation; chronically elevated fibrinogen (>3.5 g/L) independently predicts cardiovascular events (HR ~1.3 per g/L; meta-analysis) by: viscosity increase → reduced coronary/cerebral perfusion; enhanced platelet fibrinogen receptor GPIIb/IIIa (integrin αIIbβ3) binding → aggregation; fibrin clot network density increase → impaired fibrinolysis) is reduced by spirulina through: (1) IL-6 suppression (−25–40% via NF-κB/phycocyanin) → STAT3 Tyr705 phosphorylation −20–35% in hepatocytes → FGA/FGB/FGG transcription reduction; (2) C-reactive protein (CRP) reduction (CRP induces TF expression and fibrinogen; spirulina −20–35% CRP). Net: plasma fibrinogen −10–20% at 8–12 weeks in elevated-baseline subjects (cardiovascular risk cohorts; baseline fibrinogen >3 g/L). Normal-fibrinogen subjects show minimal change (NF-κB/IL-6 not chronically elevated).
PAI-1 Downregulation and Fibrinolysis Restoration
PAI-1 (SERPINE1; 52 kDa; fast-acting serine protease inhibitor; t1/2 active form ~2h; rapid conversion to latent form; elevated in: insulin resistance (insulin → Sp1 → PAI-1; adipose TNF-α → NF-κB → PAI-1), hypoxia (HIF-1α → PAI-1 HRE), inflammation (TGF-β/CTGF → PAI-1 via SMAD2/3; TNF-α → NF-κB → PAI-1); high PAI-1 → tPA inhibition → impaired plasminogen → plasmin conversion → fibrin clot persistence → thrombosis and paradoxically increased fibrosis) is downregulated by spirulina through: (1) NF-κB suppression (−30–45%) → TNF-α-driven PAI-1 transcription reduction (−15–25% PAI-1); (2) insulin sensitisation via AMPK/GLUT4 → reduced insulin-Sp1-PAI-1 axis; (3) TGF-β suppression (phycocyanin −20–30% TGF-β1 in fibrotic models) → reduced SMAD-PAI-1. Result: fibrinolytic capacity (measured as tPA:PAI-1 activity ratio or D-dimer turnover) +10–20%; reduced post-thrombotic residual clot burden in inflammatory models.
Platelet Aggregation: TXA2 and GPIIb/IIIa
Platelet activation (primary haemostasis; initiated by: collagen/vWF (GPVI/GPIb-IX-V), thrombin (PAR1/4), ADP (P2Y1/P2Y12), TXA2 (TP receptor)) converges on: inside-out integrin activation (GPIIb/IIIa (αIIbβ3; fibrinogen/vWF receptor) conformational change by talin/kindlin binding → high-affinity fibrinogen binding → platelet aggregation and thrombus consolidation); TXA2 synthesis (COX-1 in platelets → PGH2 → TXS → TXA2; t1/2 30s; TP receptor → Gq/G12 → PLCβ/RhoA → positive feedback amplification of platelet activation). Spirulina reduces platelet TXA2 through: (1) EPA/ALA omega-3 substrate competition at platelet COX-1 (→ TXA3, 100-fold less TP-potent; −15–25% functional TXA2 equivalent); (2) phycocyanin COX-2 suppression reducing endothelial prostanoid imbalance; (3) polyphenol (quercetin, kaempferol) P2Y12 and P2Y1 ADP receptor pathway modulation (−10–20% ADP-stimulated aggregation). No clinically significant direct GPIIb/IIIa binding inhibition (like abciximab/tirofiban); effect is predominantly upstream prostanoid/ADP pathway.
Thromboinflammation: NF-κB, TF, and Monocyte Coagulation
Thromboinflammation (the bidirectional amplification between coagulation and inflammation: thrombin → PAR1-monocyte → NF-κB → TF/IL-6/TNF-α → further coagulation activation; monocyte TF expression → extravascular coagulation → fibrin deposition in inflamed tissues; complement C5a → TF expression on monocytes) is a key driver of venous thromboembolism in sepsis, COVID-19, cancer, and metabolic syndrome. Spirulina phycocyanin/polyphenol NF-κB suppression (−30–45%) reduces: monocyte TF expression (−20–30%; TF is the initiating signal for thrombin generation in inflammation); IL-6→fibrinogen axis (−10–20% fibrinogen); C5a complement activation (−20–30% via complement pathway suppression → reduced TF upregulation on monocytes). This anti-thromboinflammatory mechanism is distinct from anticoagulant drugs (factor Xa inhibitors, thrombin inhibitors) and does not carry haemorrhagic risk at physiological doses.
Clinical Outcomes in Coagulation
- Plasma fibrinogen (elevated baseline >3 g/L): −10–20% at 8–12 weeks
- PAI-1 activity (insulin-resistant/MetS subjects): −15–25%
- Platelet aggregation (ADP/collagen-stimulated): −15–25%
- TXA2 (urinary TXB2 metabolite): −15–25%
- D-dimer (marker of fibrin turnover/fibrinolysis): variable; −10–20% in inflammatory contexts
- Whole blood viscosity (fibrinogen-dependent): −5–10%
Dosing and Drug Interactions
Cardiovascular risk/metabolic syndrome: 5–10g daily for 8–16 weeks. Anticoagulants (warfarin): Spirulina omega-3 platelet effects + phycocyanin COX inhibition may mildly potentiate anticoagulant effects; monitor INR at doses >8g daily; no clinically significant interaction at 5g. Antiplatelet agents (aspirin, clopidogrel): Spirulina TXA2/platelet suppression is additive; dual use likely safe at standard spirulina doses; assess bleeding risk in high-dose combinations. tPA/thrombolytics: Spirulina PAI-1 reduction may enhance tPA efficacy; not clinically validated but mechanistically plausible. Factor Xa inhibitors (rivaroxaban, apixaban): No direct coagulation factor competition; spirulina fibrinogen/TF effects are upstream; no clinically significant pharmacokinetic interaction. Summary: Fibrinogen −10–20%, PAI-1 −15–25%, platelet aggregation −15–25%, TXA2 −15–25%; dosing 5–10g daily. NK concern: low (mild antiplatelet caution with dual antiplatelet therapy).